NEW YORK (GenomeWeb News) – Cepheid said after the close of the market yesterday that it expects its third-quarter revenues to be roughly $41 million, in line with analysts' consensus estimate of $40.8 million.
The Sunnyvale, Calif.-based firm will report its third-quarter results on Oct. 28, after the close of the market.
Cepheid disclosed its Q3 revenue expectation in a statement announcing that it had hired Nicolaas Arnold to serve as executive vice president of worldwide commercial operations, effective today. Arnold joins Cepheid from Siemens, where he was regional VP for Siemens Healthcare Diagnostics in Northwest Europe with responsibility for molecular diagnostics, central lab, and point-of-care sales.
"We are looking to grow both our domestic and international markets, and this is a timely appointment that further strengthens our sales and marketing capabilities with the objective of establishing the GeneXpert System as the molecular platform of choice," Cepheid CEO John Bishop said in a statement.
Cepheid's shares were up nearly 6 percent at $13.90 in early Wednesday trade on the Nasdaq.